Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Delafloxacin - Melinta Therapeutics/Wakunaga Pharmaceutical

Next Previous
Drug Profile

Delafloxacin - Melinta Therapeutics/Wakunaga Pharmaceutical

Alternative Names: ABT-492; Baxdela; Quofenix; RX-3341; RX-3341-83; WQ-3034

Latest Information Update: 04 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wakunaga Pharmaceutical
  • Developer Abbott Laboratories; Eurofarma; Melinta Therapeutics; Menarini; Xediton Pharmaceuticals
  • Class Anti-infectives; Antibacterials; Azetidines; Fluoroquinolones; Pyridines; Small molecules; Urinary anti-infective agents
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Skin and soft tissue infections
  • Preclinical Tularaemia
  • No development reported Urinary tract infections
  • Discontinued Acute exacerbations of chronic bronchitis; Anthrax; Gonorrhoea; Intra-abdominal infections

Most Recent Events

  • 25 Sep 2024 Melinta Therapeutics suspends a phase I Bioavailability trial in Healthy volunteers in United Kingdom (PO) (NCT06612255)
  • 03 Jun 2024 Melinta Therapeutics initiates a phase I Bioavailability trial in Healthy volunteers in United Kingdom (PO) (NCT06612255)
  • 10 Jul 2023 Melinta Therapeutics receives BARDA grant for delafloxacin development in Community-acquired bacterial pneumonia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top